Meningococcemia primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Meningococcemia}} | {{Meningococcemia}} | ||
{{CMG}} | {{CMG}} | ||
==Primary Prevention== | ==Primary Prevention== | ||
Current vaccines have polysaccharides of groups A, C, Y, and W-135. No vaccine available presently for group B disease since the polysaccharide is not sufficiently immunogenic to produce a reliable antibody response in humans to be effective. | Current vaccines have polysaccharides of groups A, C, Y, and W-135. No vaccine available presently for group B disease since the polysaccharide is not sufficiently immunogenic to produce a reliable antibody response in humans to be effective. | ||
Revision as of 04:36, 19 February 2013
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia primary prevention On the Web |
|
American Roentgen Ray Society Images of Meningococcemia primary prevention |
|
Risk calculators and risk factors for Meningococcemia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Primary Prevention
Current vaccines have polysaccharides of groups A, C, Y, and W-135. No vaccine available presently for group B disease since the polysaccharide is not sufficiently immunogenic to produce a reliable antibody response in humans to be effective.
Prophylaxis
- Rifampin 600 mg PO q12h x 4 doses total or alternatively ciprofloxacin 500 mg PO x 1 in patients over 18 who cannot tolerate rifampin